Physician profile
Edgar R Salas
NPI 1265666770
$6,189.04
in general payments reported to CMS, 2019-2025
29 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $283 · 2021: $438 · 2022: $861 · 2023: $1,264 · 2024: $1,688 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954 · Travel and Lodging: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.43 |
| Travel and Lodging | $228.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,172.26 | 2019-2025 | Linzess, Creon, Skyrizi |
| Boston Scientific Corporation | $697.72 | 2019-2025 | Exalt Model D, Spyglass |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $686.61 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Phathom Pharmaceuticals, INC. | $449.41 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $419.57 | 2019-2025 | Entyvio |
| Genzyme Corporation | $214.99 | 2021-2025 | |
| Madrigal Pharmaceuticals | $166.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $158.22 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $140.72 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $135.37 | 2021-2024 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $118.07 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $97.25 | 2019-2023 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $95.25 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.88 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $79.98 | 2021-2024 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $76.39 | 2021-2022 | |
| Gilead Sciences, INC. | $75.59 | 2021-2025 | |
| Qol Medical, LLC | $60.47 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $38.84 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $35.82 | 2023 | Sunosi |
| Philips North America LLC | $30.21 | 2019 | |
| Ambu INC. | $29.41 | 2020-2023 | |
| Grifols USA, LLC | $26.37 | 2020 | |
| Mylan Specialty L.P. | $24.80 | 2024 | Yupelri |
| Lilly USA, LLC | $18.00 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $16.46 | 2024 | Suflave |
| Evoke Pharma, INC. | $14.58 | 2022 | |
| Harmony Biosciences LLC | $13.32 | 2022 | |
| Eisai INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.